PeptiDream Inc. (TSE: 4587) is a Japanese biopharmaceutical company founded in 2006 and headquartered in Kawasaki. It specializes in peptide drug discovery using its proprietary Peptide Discovery Platform System (PDPS), which generates vast libraries of macrocyclic peptides to identify potent and selective candidates for therapeutics, diagnostics, peptide-drug conjugates (PDCs), and multi-functional peptide conjugates (MPCs).
The company maintains a robust pipeline across oncology, immunology, neurology, and other areas, with programs in Phase 3 (e.g., 64Cu-ATSM for brain tumors, PSMA I&T for prostate cancer) and earlier stages, developed internally or through partnerships with firms like AstraZeneca, Merck, Novartis, and others. Its subsidiary PDRadiopharma handles radiopharmaceuticals in Japan.
PeptiDream collaborates globally to advance peptide-based innovations addressing unmet medical needs.
